Category Archives: Psoriasis

Dr Anita Ranglni: Psoriasis and Ayurvedic Treatment
Swastha bharat, Doordarshan Girnar.

By: DrAnita Ranglani

More here:
Dr Anita Ranglni: Psoriasis and Ayurvedic Treatment - Video

Denver,Colorado (PRWEB) November 29, 2014

The Psoriasis Revolution review published by Daily Gossip reveals that psoriasis actually is a commonly diagnosed disease, in people from all around the globe.

Psoriasis is described as a horrible skin disease, characterized by relapsing immune mediated redness and irritation. Patients dealing with this condition experience pain, as well as skin blotches.

To help all sufferers, Dan Crawford has released the Psoriasis Revolution program. This new program is available in a 250 page guide, revealing an effective psoriasis natural cure.

In fact, Dan had actually been a psoriasis patient himself, dealing with this condition for years. He managed to cure his disease with the use of his natural program, so Dan shared it with sufferers from all over the world.

Read the full complete review here: http://www.dailygossip.org/psoriasis-revolution-review-does-it-work-8865

The Psoriasis Revolution guide presents a holistic system that promises to help patients eliminate psoriasis in 30 to 60 days, while regaining natural internal balance. The author of this program reveals a 7 step method to stop psoriasis forever.

The method also promises to help sufferers achieve relief from all the common symptoms of psoriasis. This includes red and inflamed itchy skin, but also burning or bleeding, which will be gone in just 7 days.

Daily Gossip reveals in its Psoriasis Revolution review that the program developed by Dan is unique, as it actually focuses on fixing the root cause of psoriasis, to make sure that the disease will be overcome for good.

Learn more about this new system by using the following link: http://www.dailygossip.org/psoriasis-revolution-full-review-8864

See the article here:
Psoriasis Revolution Review Reveals Dan Crawford's New Psoriasis Cure System

Plaque Psoriasis Of Ear Pinna
This video educates on how a plaque psoriasis looks like? A lot of scales and flakes are present on right ear pinna since last 3 years, condition is quite it...

By: Vikram Yadav

More here:
Plaque Psoriasis Of Ear Pinna - Video

Psoriasis Diet Diary Week Ten
Day 74. Diet has changed, but not completely. Please see the channels I recommend below. I have added fruit, and I #39;m following the Raw til 4 philosophy. This means that I eat raw vegan until...

By: Jon Maddison

Read the rest here:
Psoriasis Diet Diary Week Ten - Video

AstraZeneca ( AZN ) and partner Amgen ( AMGN ) announced encouraging results from the pivotal, multi-arm phase III AMAGINE-2 study (n>1800) on their psoriasis candidate, brodalumab. The study compared brodalumab with both Johnson & Johnson's ( JNJ ) Stelara and placebo in treating patients suffering from moderate-to-severe plaque psoriasis.

Results showed that a greater proportion of patients treated with brodalumab 210 mg (44.4%), brodalumab weight based group (33.6%) and brodalumab 140 mg (25.7%) achieved total clearance of skin disease as measured by the Psoriasis Area Severity Index (PASI 100). In comparison, patients under Stelara achieved 21.7% and under placebo a mere 0.6%.

Moreover, according to the PASI 75 score (at least a 75% improvement in disease severity), results showed that a higher number of patients on brodalumab 210 mg (86.3%) and the brodalumab weight based group (77%) achieved the same as compared to those on brodalumab 140 mg (66.6%), Stelara (70%) and placebo (8.1%). The other key secondary endpoints of the study were also met.

We note that the companies' AMAGINE program consists of three phase III studies - AMAGINE-1, AMAGINE-2 and AMAGINE-3. While results from the AMAGINE-1 study were out in May this year, AstraZeneca and Amgen announced encouraging results from the AMAGINE-3 study earlier in the month (read more: AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial ).

With results from all the three studies out, the companies are now planning to discuss with regulatory authorities the global filing plan for the candidate which is expected next year.

Our Take

We are encouraged by the positive results from the AMAGINE program on brodalumab. Brodalumab is an important candidate for both AstraZeneca and Amgen. However, the psoriasis market currently looks extremely crowded with the presence of products like Stelara, Enbrel and Otezla.

Brodalumab is also being developed for the treatment of asthma. According to AstraZeneca, analyst estimates for brodalumab range between $0.5 billion and $1.5 billion.

Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks. A better-ranked stock in the health care sector is Allergan Inc. ( AGN ) carrying a Zacks Rank #1 (Strong Buy).

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

See original here:
AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study - Analyst Blog

Amgen Inc. (AMGN: Quote) and AstraZeneca plc's (AZN: Quote) phase III trial of psoriasis drug candidate Brodalumab has met its primary endpoint of achieving total clearance of skin disease when compared with placebo as well as Janssen Biotech Inc.'s approved drug Stelara.

The trial, dubbed AMAGINE-2, is the third and final pivotal study in the companies' phase III psoriasis program. Brodalumab is being co-developed by Amgen and AstraZeneca.

Top-line results from AMAGINE-1, comparing Brodalumab with placebo, were released in May 2014 while top-line results from AMAGINE-3, comparing Brodalumab with Stelara and placebo, were announced as recently as November 11, 2014.

The trials AMAGINE-2 and AMAGINE-3 are identical in design.

AMGN closed Tuesday's trading at $162.24, down 1.18%.

Exact Sciences Corp.'s (EXAS: Quote) Cologuard will be reimbursed at $502 per test, according to the final payment decision issued by the Centers for Medicare & Medicaid Services.

Cologuard is the first and only FDA-approved noninvasive stool DNA colorectal cancer screening test.

EXAS closed Tuesday's trading at $24.90, up 2.55%.

Intra-Cellular Therapies Inc. (ITCI: Quote) has enrolled the first patient in its phase III trial of ITI-007 for the treatment of schizophrenia.

The trial, dubbed ITI-007-301, is designed to enroll over 400 patients with an acutely exacerbated episode of schizophrenia who will be randomized to receive one of three treatments namely, 60 mg ITI-007, 40 mg ITI-007, or placebo in a 1:1:1 ratio. Top-line results from this trial could be available as early as the fourth quarter of 2015.

Continued here:
Psoriasis Drug Trial Meets Goals, Reimbursement Rate For Cologuard Finalized

Published 25 November 2014

Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA (apremilast), the Company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications:

Psoriasis is an immune mediated skin condition characterised by raised scaly lesions on the skin. It affects approximately 14 million people across Europe and about 125 million people worldwide.

Plaque psoriasis, also called psoriasis vulgaris, is the most common form of the disease, representing about 80 percent of cases. Up to 30 percent of people with psoriasis may develop psoriatic arthritis, which involves pain and swelling in jointsand other manifestations and may lead to significant disability.

"This CHMP positive opinion is an important step forward for people with psoriasis and psoriatic arthritis in Europe. These immune mediated diseases are frequently debilitating and cause severe physical and emotional pain to the individual," stated Tuomo Ptsi, President, Celgene Europe, the Middle East and Africa (EMEA).

"We are proud to have moved one step closer to offering patients OTEZLA, a new, oral treatment approach that could significantly help control their symptoms and make a considerable difference to their quality of life."

In the ESTEEM studies, which form the basis of CHMP's positive opinion for apremilast in psoriasis, treatment resulted in significant and clinically meaningful improvements in plaque psoriasis as measured by PASI-75 (a 75 percent improvement in the Psoriasis Area Severity Index) scores at week 16, the primary endpoint.

Patients on apremilast also benefited from significant improvements in difficult to treat areas, such as nail and scalp, and itch, known to have a marked impact on patients' quality of life and perception of disease severity.

In the PALACE program, which forms the basis for CHMP's positive opinion for apremilast in psoriatic arthritis, treatment resulted in significant and clinically meaningful improvements in the signs and symptoms of psoriatic arthritis, as measured by the modified ACR-20 (a 20 percent improvement in the American College of Rheumatology disease activity criteria) response at 16 weeks, the primary endpoint.

Patients on apremilast showed improvement across multiple disease manifestations specific to psoriatic arthritis, such as swollen and tender joints, as well as dactylitis, enthesitis and overall physical function.

Continued here:
Celgene gets positive CHMP opinion for OTEZLA to treat psoriasis and psoriatic arthritis

Novartis AG ( NVS ) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion on the approval of Cosentyx (secukinumab, formerly known as AIN457). Cosentyx is the first IL-17A inhibitor to be recommended as a first-line treatment option for psoriasis patients who require systemic therapy in Europe.

Cosentyx works by inhibiting IL-17A, a protein that is found in high concentrations in skin affected by the disease.

The CHMP's favorable opinion comes shortly after Cosentyx received a unanimous recommendation from the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) last month -- a final decision from the FDA should be out in early 2015. The favorable opinion of the CHMP will now be reviewed by the European Commission with a final decision expected in the next couple of months.

With the CHMP in favor of approving Cosentyx, we believe chances of approval are high. Once approved, Cosentyx will be entering an extremely crowded psoriasis market given the presence of products like Stelara, Enbrel and Otezla.

Moreover, new treatments are currently in development including Amgen ( AMGN )/AstraZeneca's ( AZN ) brodalumab.

However, with Cosentyx consistently demonstrating very high skin clearance, including superiority to Enbrel in the head-to-head FIXTURE study, and given the high rate of dissatisfaction among patients regarding existing treatment options, Cosentyx could rapidly gain share once approved.

Meanwhile, Novartis is evaluating Cosentyx for several other indications including ankylosing spondylitis and psoriatic arthritis among others.

Novartis currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Allergan Inc. ( AGN ) carrying a Zacks Rank #1 (Strong Buy).

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

Read the original post:
Novartis' Psoriasis Drug Cosentyx Backed for EU Approval - Analyst Blog

Homeopathic Treatment for Psoriasis Types, Symptoms, Medicines | Doctors Talk
Doctors Talk is Special Program by CVR Health TV in which a Specialist Doctor will give solutions to health problems and treatments to that particular health problem. Watch CVR Health, the...

By: CVR Health TV

Read more:
Homeopathic Treatment for Psoriasis Types, Symptoms, Medicines | Doctors Talk - Video

Psoriasis Explained
A dermatologist explains how this skin condition is recognised and treated and the challenging effects it can have on an individual. Video streamed by http://www.AllthingsScience.com All Things Science.

By: Davies Robinson

Read more:
Psoriasis Explained - Video